Physician profile
Leena Daniel
NPI 1881252880
$2,254.81
in general payments reported to CMS, 2019-2025
19 companies · $713 in 2025
The $713 reported for 2025 was more than what 81% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.24 · 2022: $225 · 2023: $437 · 2024: $804 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.03 |
| Education | $281.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $272.84 | 2021-2025 | Pomalyst, Reblozyl, Breyanzi |
| Janssen Biotech, INC. | $263.66 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Karyopharm Therapeutics INC. | $261.66 | 2023-2025 | Xpovio |
| Incyte Corporation | $237.53 | 2022-2025 | Monjuvi |
| Janssen Scientific Affairs, LLC | $224.09 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Lilly USA, LLC | $175.75 | 2024-2025 | Jaypirca |
| Btg International INC. | $116.84 | 2023-2025 | Voraxaze |
| Regeneron Pharmaceuticals, INC. | $116.21 | 2024 | |
| Adc Therapeutics America, INC. | $103.16 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.99 | 2022 | |
| Seagen INC. | $83.00 | 2025 | |
| Abbvie INC. | $63.39 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $48.61 | 2022-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Astrazeneca Pharmaceuticals Lp | $47.16 | 2023-2024 | Calquence |
| Pfizer INC. | $39.80 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.97 | 2022 | |
| Legend Biotech USA INC. | $24.78 | 2022 | |
| Azurity Pharmaceuticals, INC. | $23.07 | 2024 | Vivimusta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leena Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.